Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SYDNEY, Australia, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 3116909 entitled “Antibody...
-
Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trialPreliminary Overall Response Rate (ORR) of 41% from stage 11 of Part A ORR compares favourably to standard...
-
TACTI-002 patient recruitment updateSix patients now enrolled and dosed in INSIGHT-004, 6 mg cohort completeSignificant eftilagimod alpha clinical data expected in coming months:° AIPAC Phase II -...
-
Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrolizumabDeep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in...
-
SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
-
SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
-
Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2Recruitment of cohort 2 of Part A of TACTI-002,...
-
SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
-
SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody...
-
SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...